Oral and injectable semaglutide are the same molecule. The tablet is taken daily on an empty stomach with an absorption enhancer; the injection is weekly. Wegovy tablets are approved for weight reduction in adults, and trial averages for both forms were broadly similar.
Oral and injectable semaglutide contain the same active molecule, but they reach your bloodstream in very different ways. The injection is given once a week under the skin. The tablet is taken once a day on an empty stomach, with a small amount of water, and it relies on an absorption enhancer to get through the stomach wall. Wegovy now comes in both forms for weight reduction in adults, and in separate trials the average results for the two were in a broadly similar range.
The practical differences are mostly about routine. Here is what the prescribing information describes.
| Injection (Wegovy) | Tablet (Wegovy) | |
|---|---|---|
| How often | Once weekly, same day each week | Once daily |
| Timing | Any time of day, with or without meals | In the morning on an empty stomach |
| Liquid | Not applicable | Plain water only, up to 4 ounces |
| After taking | No wait required | Wait at least 30 minutes before eating, drinking or taking other oral medicines |
| How | Under the skin of the abdomen, thigh or upper arm | Swallow whole; do not split, crush, chew or dissolve |
| Missed dose | Depends on how long until the next scheduled dose | Skip it and take the next tablet the following day |
Dose amounts and escalation steps are set by the prescriber and are not covered here.
Semaglutide is a peptide, a short chain of amino acids. Taken by mouth without help, peptides are broken down by digestive enzymes and absorbed poorly. A 2018 study in Science Translational Medicine, conducted by the manufacturer, showed how the tablet gets around this. Semaglutide is co-formulated with SNAC (salcaprozate sodium). In clinical and animal studies, absorption took place in the stomach rather than the intestine, in a small area right around the dissolving tablet, and it required SNAC. The researchers found SNAC protects semaglutide from enzymes through local buffering and only briefly enhances absorption.
That explains the instructions. Food, other drinks or a large glass of water in the stomach can interfere with the small zone where absorption happens, which is why the label limits water and asks you to wait before eating.
It also explains why tablet and injection strengths look so different. The label for the semaglutide tablets used in diabetes (Rybelsus and Ozempic tablets) reports absolute bioavailability of roughly 0.4 to 1 percent for Rybelsus and 1 to 2 percent for Ozempic tablets, meaning only a small fraction of each tablet is absorbed. Tablets therefore contain much more semaglutide by weight than a weekly injection. The same label notes that its two tablet products are not interchangeable on a milligram basis, and the Wegovy label lists specific steps for moving between its injection and tablets.
There is no single head-to-head trial in the sources here comparing the Wegovy tablet and injection for weight. The best available picture comes from two placebo-controlled trials with similar designs.
Because the trials differed in size, length and location, the numbers should not be read as a precise comparison. Both were funded by the manufacturer. These are group averages, and individual responses vary widely.
On side effects, the Wegovy label states that the types and frequency of common adverse reactions in the tablet trial were similar to those seen with the injection. It also lists a few tablet-specific findings: dysesthesia (an altered skin sensation) in 5 percent of tablet users versus none on placebo, and gastrointestinal reactions leading to discontinuation in 3.4 percent versus 2 percent.
According to the current Wegovy label, both forms are indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related condition, and to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Only the injection is indicated for pediatric patients 12 and older with obesity and for noncirrhotic MASH with moderate to advanced fibrosis.
Rybelsus and Ozempic tablets are a different label, indicated for adults with type 2 diabetes. For an overview of every brand name, see The GLP-1 Names Explained.
Some pharmacies sell compounded sublingual (under the tongue) or orally disintegrating semaglutide. A 2026 review in the Annals of Pharmacotherapy that searched compounding sites found these formulations and concluded that whether they offer any advantage over the approved oral tablets has not been determined, and that the correct dose, efficacy and safety of these non-swallowed products are lacking. Compounded products are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are sold.
In separate trials, the Wegovy tablet averaged -13.6 percent body weight change at 64 weeks and the weekly injection averaged -14.9 percent at 68 weeks, each compared with placebo. Those results are in a similar range, but the trials were different, so they cannot be compared precisely. Individual results vary.
Semaglutide from the tablet is absorbed in the stomach in a small area around the dissolving tablet, with help from SNAC. Food, other drinks or medicines taken too soon can reduce how much is absorbed. The label asks for at least 30 minutes before anything else by mouth.
Both contain semaglutide, but they are separate products with different labels. Rybelsus is approved for type 2 diabetes. Wegovy tablets are approved for weight reduction and cardiovascular risk reduction in adults. Their strengths are not interchangeable.
The Wegovy label describes how a prescriber can move a patient between the two forms. Because the strengths do not convert milligram for milligram, a switch should only happen under your prescriber's direction.
The best form is the one that fits your health history, your other medicines and your daily routine. A licensed provider can talk through the trade-offs, including how a daily tablet would interact with any medications you already take. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
An underactive thyroid can add modest weight and fatigue, so a TSH test is a sensible check if you have symptoms. Separately, GLP-1 labels warn against use with a personal or family history of medullary thyroid cancer or MEN 2, so share your full thyroid history.
Read article